interferon in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Pandit, 2021 0.95 [0.02; 50.33]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
1.86 [0.62 ; 5.58 ] Kalil (ACTT-3), 2021, Pandit, 2021, Shashi Bhushan, 2021 3 0% 1,258 moderate not evaluable deathsdetailed results Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25]
Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92]
Fu, 2020 1.00 [0.02; 51.66]
Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
Pandit, 2021 0.95 [0.02; 50.33]
Rahmani, 2020 0.29 [0.05; 1.56]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
SOLIDARITY (interferon), 2020 1.16 [0.96; 1.40]
Synairgen SG016, 2020 0.16 [0.01; 3.31]
0.86 [0.53 ; 1.41 ] Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Fu, 2020, Kalil (ACTT-3), 2021, Pandit, 2021, Rahmani, 2020, Shashi Bhushan, 2021, SOLIDARITY (interferon), 2020, Synairgen SG016, 2020 9 20% 5,685 moderate not evaluable deaths (time to event analysis only)detailed results Kalil (ACTT-3), 2021 1.74 [0.51; 5.93]
1.74 [0.51 ; 5.93 ] Kalil (ACTT-3), 2021 1 0% 969 NA not evaluable clinical deteriorationdetailed results Synairgen SG016, 2020 0.50 [0.18; 1.38]
0.50 [0.18 ; 1.38 ] Synairgen SG016, 2020 1 0% 101 NA not evaluable clinical improvementdetailed results Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Synairgen SG016, 2020 2.32 [1.07; 5.04]
1.39 [0.78 ; 2.47 ] Darazam (COVIFERON Interferon beta-1a), 2021, Kalil (ACTT-3), 2021, Shashi Bhushan, 2021, Synairgen SG016, 2020 4 68% 1,251 moderate not evaluable clinical improvement (14-day)detailed results Kalil (ACTT-3), 2021 1.01 [0.79; 1.29]
Pandit, 2021 8.77 [0.94; 81.67]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
1.16 [0.50 ; 2.72 ] Kalil (ACTT-3), 2021, Pandit, 2021, Shashi Bhushan, 2021 3 50% 1,250 moderate not evaluable clinical improvement (28-day)detailed results Synairgen SG016, 2020 3.15 [1.39; 7.14]
3.15 [1.39 ; 7.14 ] Synairgen SG016, 2020 1 0% 101 NA not evaluable clinical improvement (7-day)detailed results Shashi Bhushan, 2021 1.91 [1.03; 3.53]
1.91 [1.03 ; 3.53 ] Shashi Bhushan, 2021 1 0% 222 NA not evaluable clinical improvement (time to event analysis only)detailed results Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12]
Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18]
Kalil (ACTT-3), 2021 0.99 [0.87; 1.13]
Rahmani, 2020 3.41 [1.33; 8.73]
1.66 [0.90 ; 3.06 ] Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Kalil (ACTT-3), 2021, Rahmani, 2020 4 74% 1,115 moderate not evaluable death or ventilationdetailed results SOLIDARITY (interferon), 2020 1.05 [0.90; 1.23]
Synairgen SG016, 2020 0.38 [0.09; 1.63]
0.83 [0.35 ; 1.93 ] SOLIDARITY (interferon), 2020, Synairgen SG016, 2020 2 46% 4,100 moderate not evaluable hospital dischargedetailed results Rahmani, 2020 3.44 [0.64; 18.49]
Synairgen SG016, 2020 1.63 [0.61; 4.35]
1.97 [0.84 ; 4.60 ] Rahmani, 2020, Synairgen SG016, 2020 2 0% 167 moderate not evaluable hospitalizationdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
1.00 [0.14 ; 7.34 ] Jagannathan, 2020 1 0% 120 NA not evaluable mechanical ventilationdetailed results Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67]
Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67]
Rahmani, 2020 0.29 [0.05; 1.56]
0.75 [0.34 ; 1.69 ] Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Rahmani, 2020 3 0% 146 moderate not evaluable viral clearance detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
Pandit, 2021 2.33 [0.55; 9.83]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
1.61 [0.61 ; 4.25 ] Jagannathan, 2020, Pandit, 2021, Shashi Bhushan, 2021 3 82% 401 moderate not evaluable viral clearance (time to event analysis only)detailed results Jagannathan, 2020 0.81 [0.56; 1.18]
0.81 [0.56 ; 1.18 ] Jagannathan, 2020 1 0% 120 NA not evaluable viral clearance by day 14detailed results Pandit, 2021 10.23 [1.12; 93.35]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
0.18 [0.00 ; 435.69 ] Pandit, 2021, Shashi Bhushan, 2021 2 98% 1,359 moderate not evaluable viral clearance by day 7detailed results Pandit, 2021 2.33 [0.55; 9.83]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
2.69 [1.48 ; 4.87 ] Pandit, 2021, Shashi Bhushan, 2021 2 0% 281 moderate not evaluable ICU admissiondetailed results Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71]
Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94]
Rahmani, 2020 0.37 [0.14; 1.00]
0.49 [0.24 ; 1.00 ] Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Rahmani, 2020 3 0% 146 moderate not evaluable recoverydetailed results Synairgen SG016, 2020 2.19 [1.03; 4.67]
2.19 [1.03 ; 4.67 ] Synairgen SG016, 2020 1 0% 101 NA not evaluable serious adverse eventsdetailed results Jagannathan, 2020 1.00 [0.14; 7.34]
Pandit, 2021 0.95 [0.02; 50.33]
0.99 [0.17 ; 5.88 ] Jagannathan, 2020, Pandit, 2021 2 0% 159 moderate not evaluable superinfectiondetailed results Rahmani, 2020 0.18 [0.02; 1.59]
0.18 [0.02 ; 1.59 ] Rahmani, 2020 1 0% 66 NA not evaluable adverse eventsdetailed results Jagannathan, 2020 1.33 [0.63; 2.78]
Pandit, 2021 1.68 [0.47; 5.97]
1.41 [0.74 ; 2.67 ] Jagannathan, 2020, Pandit, 2021 2 0% 159 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-19 10:12 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 517,881,904,882,897,896,899,1235,898,687,740,883,947
- roots T: 290
